Monoclonal Antibody to Receptor Interacting Serine Threonine Kinase 3 (RIPK3)
| Code | Size | Price |
|---|
| MAE639Ra23-20ul | 20ul | £97.00 |
Quantity:
| MAE639Ra23-100ul | 100ul | £186.00 |
Quantity:
| MAE639Ra23-200ul | 200ul | £252.00 |
Quantity:
| MAE639Ra23-1ml | 1ml | £585.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
RIP3; RIP-like protein kinase 3; Receptor-interacting protein 3
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Ig Isotype:
IgG1 Kappa
Immunogen:
RPE639Ra01-Recombinant Receptor Interacting Serine Threonine Kinase 3 (RIPK3)
Item Name:
Receptor Interacting Serine Threonine Kinase 3
Potency (Clone Number):
D9
Source:
Monoclonal antibody preparation
Subcategory:
Monoclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Receptor Interacting Serine Threonine Kinase 3 (RIPK3) | RPE639Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||